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Abstract
Background: Exposing healthy human volunteers to Plasmodium falciparum-infected mosquitoes is an accepted tool to
evaluate preliminary efficacy of malaria vaccines. To accommodate the demand of the malaria vaccine pipeline, controlled
infections are carried out in an increasing number of centers worldwide. We assessed their safety and reproducibility.
Methods: We reviewed safety and parasitological data from 128 malaria-naı ¨ve subjects participating in controlled malaria
infection trials conducted at the University of Oxford, UK, and the Radboud University Nijmegen Medical Center, The
Netherlands. Results were compared to a report from the US Military Malaria Vaccine Program.
Results: We show that controlled human malaria infection trials are safe and demonstrate a consistent safety profile with
minor differences in the frequencies of arthralgia, fatigue, chills and fever between institutions. But prepatent periods show
significant variation. Detailed analysis of Q-PCR data reveals highly synchronous blood stage parasite growth and
multiplication rates.
Conclusions: Procedural differences can lead to some variation in safety profile and parasite kinetics between institutions.
Further harmonization and standardization of protocols will be useful for wider adoption of these cost-effective small-scale
efficacy trials. Nevertheless, parasite growth rates are highly reproducible, illustrating the robustness of controlled infections
as a valid tool for malaria vaccine development.
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Introduction
Deliberate exposure of healthy human volunteers to the bites of
laboratory-reared Plasmodium falciparum (Pf)-infected mosquitoes in
a controlled experimental setting is an accepted tool in malaria
vaccine development. Such controlled human malaria infection
(CHMI) trials can be used to investigate Pf immunology [1] or to
provide data on the efficacy of malaria vaccine candidates [2] as a
precursor to more costly and logistically challenging Phase IIb field
efficacy trials. In CHMI, development of blood stage parasites in
test subjects is assessed by blood smears at regular time points and
anti-malarial treatment is given as soon as blood stage parasites are
detected microscopically, keeping blood stage parasitemia low
(treatment threshold: four parasites/ml) and confined to a short
(two to eight day) period [3]. A comparison of the interval between
exposure and parasite detection (prepatent period) among
vaccinated and control subjects, together with sterile efficacy rates
in vaccinees, provides an important efficacy estimate for the
candidate vaccine. Because prepatent periods without information
on parasite growth rates provide only an estimate of vaccine
efficacy, molecular techniques have been developed to more
accurately quantify blood parasites and provide parasite kinetic
data [3,4,5].
Decades of extensive efforts to find an efficacious malaria
vaccine have lead to the development of about 38 Pf candidate
(sub-unit) malaria vaccines or vaccine components (www.who.int/
vaccine_research/links/Rainbow/en/index.html). To meet the
demands of the growing malaria vaccine development pipeline,
CHMI will likely be conducted in an increasing number of sites
worldwide. We have performed a comparative analysis of safety
and parasitological data from trials performed at the Radboud
University Nijmegen Medical Centre (RUNMC), The Nether-
lands, and the University of Oxford in the United Kingdom, two
of a total of five different institutions and the only non-US
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data were compared with a previously published report from the
US Military Malaria Vaccine Program (USMMVP), Naval
Medical Research Center Component, Silver Spring, Maryland
[6]. Based on this data, we provide a perspective on future
strengthening of and improvements to the CHMI model.
Methods
Volunteers participating in CHMI studies performed at the
RUNMC in Nijmegen, The Netherlands and the Centre for
Clinical Vaccinology and Tropical Medicine at the University of
Oxford, United Kingdom were included from 1999 until 2010 and
from 2000 to 2010 respectively. Data were compared with a
previously published report of trials performed between 1998 and
2002 at the USMMVP, Silver Spring, Maryland [6].
Patient population
Data from three different cohorts were assessed. A summary of
the cohort characteristics is provided in Table 1. Data from eight
studies at RUNMC were analyzed in two cohorts [7,8,9,10]. The
first cohort (RUNMC I) has been previously described by Verhage
et al [7]. Five volunteers from this cohort received anti-malarial
treatment with 48 hours delay after parasites were detected by
microscopy. The RUNMC II cohort includes volunteers from
2004 onwards, when more stringent cardiovascular inclusion
criteria (based on SCORE cardiovascular risk [11]) were adapted
following a case of myocardial infarction in a malaria-negative
volunteer [7] and an increased threshold for microscopic parasite
detection was implemented. RUNMC II includes 12 volunteers
who participated in a candidate malaria vaccine trial, but were not
protected (Nieman et al. manuscript in preparation). All other volunteers
were unimmunized.In Oxford, 65 infectivity control volunteers
participated in 14 studies [12,13,14,15,16,17,18].
All included subjects were healthy, male and female, malaria-
naı ¨ve volunteers between the ages of 18 and 50 years(Table 1).
Malaria naivete ´ was confirmed by medical and travel history.
Volunteers from the RUNMC cohorts were also confirmed
negative for antibodies against blood-stage Pf by ELISA [19].
Volunteers were excluded in case of known allergies to anti-
malarials, pregnancy, systemic disease or chronic use of medica-
tion. Volunteers were screened by a physician based on medical
history, physical examination, complete blood count, liver and
renal function tests, pregnancy test and serological testing for HIV,
hepatitis B and C. Volunteers provided written informed consent
and all studies were approved by either the RUNMC Committee
on Research involving Human Subjects or Central Committee on
Research involving Human Subjects (CMO 0004–0090, 0011–
0262, 2001/203, 2002/170, 2004/129, 2006/207,
NL14715.000.06, NL24193.091.09) or the Oxfordshire Research
Ethics Committee or the UK Gene Therapy Advisory Committee
(C01.111, C02.069, C02.152, C02.153, C02.266, C02.268,
C02.293, C02.305, CL03.100, C03.088, 04/Q1604/93, 06/
Q1604/55, 05/Q1604/69, GTAC 160-02).
Infection procedures
Anopheles stephensi mosquitoes were infected with the NF54 strain
of Pf (RUNMC) or 3D7, a clone originally derived from NF54,
(Oxford) following previously described procedures [20]. Both
strains are chloroquine sensitive (data not shown).
Fixed numbers of mosquitoes were allowed to bite volunteers
during five (Oxford) or ten (RUNMC) minutes. Fully blood-
engorged mosquitoes were confirmed positive for salivary gland
sporozoites by dissection (a threshold of .10 sporozoites/gland
was used in all centers). If necessary, feeding sessions were
repeated until exactly the predefined number of infected
mosquitoes were fully engorged, i.e. five mosquitoes, except for
the RUNMC I cohort, where volunteers were exposed to the bites
of four to seven mosquitoes (Table 1). Monitoring took place twice
(Oxford) or thrice daily (RUNMC) using microscopy of Giemsa-
stained blood smears starting on day five at RUNMC or on the
afternoon of day six at Oxford. Volunteers were treated with a
standard therapeutic regimen of chloroquine, arthemether/
lumefantrine or atovaquone/proguanil as soon as microscopy
confirmed the presence of parasites or by the discretion of the
physician.
Trial volunteers were followed on an outpatient basis and lived
in the vicinity of the hospital. An active tracking policy using
mobile phones and/or home visits was operational at both
institutions during the monitoring period. Adverse events were
recorded at every visit. Investigators evaluated the potential
relation of adverse events with trial procedures. All probable or
possible related events were included in the analysis, with
exception of the five volunteers for whom anti-malarial treatment
was delayed by 48 hours. The USMMVP report included adverse
events from day seven after challenge [6]. Severity of symptoms in
RUNMC II and the USMMVP report were assessed according to
standard guidelines (http://www.fda.gov/
BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/
Vaccines/ucm074775.htm). Mild symptoms (grade 1) did not
interfere with daily activities, moderate symptoms (grade 2)
interfered with daily activities, severe symptoms (grade 3)
prevented daily activity. Symptom severity was not consistently
assessed in the other cohorts, with exception of fever, which was
graded mild when 37.5 to 37.9uC, moderate when 38 to 38.9uC
and severe when $39uC in all cohorts. All centers recorded oral
temperatures, which were measured at least once daily, either by
volunteers themselves or by the attending physician at the clinical
site. RUNMC also recorded auricular temperatures at the clinical
site up to three times daily. Serious adverse events (grade 4) were
defined according to International Conference of Harmonization
Good Clinical Practice Guidelines.
Clinical hematological laboratory data were available on a daily
basis from day five post-challenge until three days after anti-
malaria treatment for RUNMC cohorts. Biochemical parameters
in RUNMC cohorts were assessed once, at three days after anti-
malarial treatment. Clinical laboratory parameters in Oxford were
not routinely recorded during challenge in any trials. For the
USMMVP cohort, clinical laboratory parameters were reported at
days 10–12 after challenge.
Parasitological data
Prepatent period was defined as time from exposure to positive
thick smear. The threshold for microscopic detection of parasites
varied between cohorts depending on the local standard operating
procedure (Table 1). Centres use different microscopes, blood
volume and slide surface area. RUNMC and Oxford readers
complete 200 fields, yielding a threshold of approximately two
parasites per ml blood in RUNMC I and Oxford (slide was deemed
positive if one parasite was found), which was confirmed by Q-
PCR in Oxford. A threshold of four parasites per ml blood was
achieved in RUNMC II (slide was deemed positive if two parasites
were found). USMMVP readers completed 5 passes (72 fields/
pass), yielding a threshold of approximately 3 parasites per ml
blood (slide positive if two parasites were found). In all centers,
slides were read by two independent readers at 10006 magnifi-
cation.
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Oxford to support microscopy. Parasite densities were measured
by Q-PCR for RUNMC and Oxford cohorts as previously
described [3,5]. Although methodology of the Q-PCR differed,
there was no inter-institutional difference in measured densities,
confirmed by an exchange of samples between both institutions
(data not shown). Peak parasitemia was defined as the highest
parasite density during infection measured by Q-PCR. Any cycle
threshold above 45 was plotted as zero parasitemia. For
calculations, these samples were given a value of half the detection
threshold (ten parasites/ml).
Data analysis
Data were assessed in SPSS 16.0 with correction for multiple
analyses. Differences between frequencies and prepatent period
were compared by Kruskal-Wallis tests when comparing multiple
groups or Mann-Whitney U tests when comparing two groups.
Dunn’s multiple comparisons test was performed as post-hoc
analysis when appropriate. Analysis of parasitological PCR data
was performed on log-transformed data using independent-
samples t-test when comparing two groups and one-way ANOVA
when comparing three groups. The multiplication rate of blood
stage parasites was calculated by the ratio of the geometric mean
parasitemia in the second cycle with the first cycle (day 8.6–10.5 vs
6.6–8.5) or the third cycle with the second cycle (day 10.6–12.5 vs
8.6–10.5), or if possible, the mean of both ratios.
Correlations were assessed by Pearson’s correlation when
parametric and Spearman’s when non-parametric. Two-sided p-
values below 0.05 were considered significant unless stated
otherwise.
Results
Demographics
A total of 128 volunteers were grouped into three different
cohorts: RUNMC I and II and Oxford and compared to
published data from 47 infected individuals at USMMVP [6],
for a total of 175 volunteers. Individuals were generally 20–
40 years old, with equal distribution between male and female
participants (Table 1). There were no significant differences in sex
distribution between the different cohorts (Kruskal-Wallis,
p=0.22), but RUNMC II volunteers were significantly younger
(Kruskal-Wallis, p,0.001) due to more stringent cardiovascular
inclusion criteria.
Clinical manifestations
One hundred percent of volunteers developed signs and
symptoms of uncomplicated malaria; there was no severe malaria
according to WHO criteria (http://whqlibdoc.who.int/
publications/2010/9789241547925_eng.pdf). Five serious adverse
events (grade 4) occurred; three volunteers were admitted to the
hospital for intravenous rehydration and directly observed intake
of anti-malarial medication because of vomiting, two from
Table 1. Cohort characteristics.
Cohort
RUNMC
I
RUNMC
II Oxford USMMVP
Number of volunteers 20 43 65 47
Demographics
Mean age (stdev) 29 (8.3) 22 (2.5) 27 (6.2) 27 (UNK)
Sex (males) 10 14 32 27
Immunized, non-protected volunteers 0 12 0 31
Methodology
Mosquito strain NF54 NF54 3D7 NF54
Number of infected mosquitoes 4–7 5 5 5
Exposure time to mosq. (min) 10 10 5 5
Threshold microscopy (parasites/ul) 2 4 2 3
Clinical follow-up frequency (times daily) 3 3 2 1
Anti-malarial treatment
Chloroquine 20 30 47
Artemether/lumefantrine 33 35
Atovaquone/proguanil 10
Parasitological data
Median prepatent period (days) 9.0 10.0 11.2 11.0
Range prepatent period (days) 7.3–10.3 7.0–12.3 8.0–14.5 9.0–14.0
Geometric mean peak parasitemia (Pf/ml) 7076 15901 9055
Geometric mean parasitemia first cycle (Pf/ml) 567 456 48
Geometric multiplication factor 11.8 11.1 11.6
Laboratory safety parameters
Mean platelet count day 7–10 (x10e9/l) 242 261 239
References [7] [8–10] [11–17] [6]
doi:10.1371/journal.pone.0038434.t001
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discharged within 24–48 hours without sequelae. One volunteer
from RUNMC II reported retrosternal chest pain two days after
treatment with arthemeter-lumefantrine [21]. She was admitted,
diagnosed as acute coronary syndrome and treated accordingly.
Apart from acute coronary syndrome, myocarditis can be
considered as a final diagnosis. A definite relationship between
the cardiac event and malaria could not be established. One
volunteer from Oxford was briefly admitted for observation of a
suspected allergic reaction to chloroquine that resolved spontane-
ously and rapidly.
The most frequently reported solicited adverse events were
headache, fever and myalgia (Table 2). Approximately 20–50% of
volunteers experienced severe (grade 3) adverse events. Arthralgia,
fatigue and chills were significantly more frequently reported in
Oxford (chills) and USMMVP (arthralgia, fatigue) while fever
(temperature .37.5uC) occurred with significant higher frequency
in RUNMC and USMMVP.
Unsolicited adverse events were infrequent and never severe,
and all resolved spontaneously. Events included vasovagal
collapse, epistaxis, flatulence, insomnia, tinnitus, hyperesthesia,
psychiatric complaints associated with chloroquine [7], pleuritic
chest pain, sore throat, migraine, gingivitis, palpitations, numbness
in fingers, dizziness, drowsiness, photosensitivity and stiff neck.
Laboratory safety parameters
Clinical laboratory parameters in RUNMC and USMMVP did
not show significant abnormalities in hemoglobin content;
parameters were not routinely available in Oxford. The majority
of volunteers experienced a mild to moderate decrease in
leucocyte count, none of which was severe (,1.5610
9/l). Thirteen
of 110 volunteers (12%) showed a severe decrease in platelet count
(,100610
9/l). All instances occurred after initiation of anti-
malarial treatment, three in the delayed treatment group in
RUNMC I, nine in RUNMC II and one in USMMVP. In all
events platelet counts fully recovered without complications of
bleeding. There were no differences in mean platelet count
between the cohorts at similar timepoints (Table 1).
Volunteers with a severe decrease in platelets showed a longer
period of submicroscopic parasitemia (Mann-Whitney p=0.03), a
trend towards a longer prepatent period (Mann-Whitney
p=0.079), but no higher peak parasite density (p=0.29). The
Table 2. Adverse event frequency and duration for three different cohorts.
RUNMC
I
(12) #
RUNMC
II
(10,11)
USMMVP
(12) Oxford
#
Frequency Duration Frequency Duration Frequency Duration Frequency Duration
Symptom no % mean SD no % mean SD no % mean SD no % mean SD
Total
(%) p-value*
headache 19 95 4.74 2.02 40 93 3.75 2.58 47 100 3.75 2.20 61 95 1.30 0.71 96 0.44
fever 18 90 3.56 3.33 37 86 1.92 0.87 37 79 - - 20 31 0.62 0.52 64 ,0.001
myalgia 13 65 2.92 1.44 32 74 2.86 2.25 38 81 3.00 1.82 48 75 0.58 0.52 75 0.88
arthragia - ---2 52 . 5 6 3 . 4 5 1 7 3 6 2 . 3 5 2 . 2 9 - ---1 1,0.001
malaise 13 65 4.69 3.50 28 65 2.16 1.14 44 94 2.61 1.72 - - - - 49 0.01
fatigue 9 45 3.11 1.54 26 60 4.64 4.36 47 100 3.96 1.69 - - - - 47 ,0.001
dizziness 6 30 2.75 2.22 16 37 0.95 2.73 24 51 1.67 0.82 - - - - 26 0.44
chills 5 25 2.00 0.82 14 33 1.31 0.65 40 85 2.28 1.26 48 75 1.17 0.96 61 ,0.001
abdominal pain 2 10 2.33 3.21 12 28 1.62 1.82 17 36 1.82 1.55 - - - - 18 0.25
nausea 9 45 3.33 2.00 21 49 1.83 1.55 29 62 1.83 1.20 39 61 1.18 0.65 56 0.59
vomiting 2 10 1.00 0.00 7 16 0.73 0.74 6 13 1.68 0.41 - - - - 9 0.51
diarrhoea 4 20 2.00 2.71 3 7 0.51 0.57 12 26 1.67 0.89 16 23 0.58 0.52 20 0.15
cough 4 20 3.80 6.30 2 5 0.05 0.21 9 19 2.57 1.81 - - - - 9 0.08
Severe symptoms
(grade III)
a n y - ---2 1 4 9 3 . 0 0 2 . 3 6 1 0 2 1 2 . 3 0 1 . 2 5 - ---3 40 . 0 1
h e a d a c h e - ---6 1 4 5 . 1 7 3 . 5 5 3 6 2 . 0 0 1 . 0 0 - ---1 00 . 2 6
fever 8 40 - - 15 35 1.92 0.94 - - - - - - - - 37 ,0.001
myalgia - ---0 00 . 0 0 0 . 0 0 1 3 3 . 0 0 0 . 0 0 - ---1 0 . 2 6
malaise - ---7 1 6 2 . 5 0 1 . 2 5 3 7 1 . 3 3 0 . 5 8 - ---1 10 . 2 5
fatigue - ---2 57 . 4 0 0 . 5 7 2 4 3 . 5 0 1 . 1 2 - ---4 0 . 7 0
n a u s e a - ---0 00 . 0 0 0 . 0 0 1 3 1 . 0 0 0 . 0 0 - ---1 ,0.001
chills - ---0 00 . 0 0 0 . 0 0 3 8 2 . 0 0 0 . 8 2 - ---3 0 . 0 6
vomiting - ---1 22 . 0 0 0 . 0 0 0 0 -- - ---1 0 . 4 4
diarrhoea - ---0 00 . 0 0 0 . 0 0 0 0 -- - ---0 0 . 1 0
*p,0.002 was considered significant when adjusted for multiple testing.
#Adverse events recorded in RUNMC I and Oxford were not graded.
doi:10.1371/journal.pone.0038434.t002
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(Spearman p=0.005).
No abnormalities of urea and creatinine were found, but
USMMVP reported six cases of hemoglobinuria and one case of
proteinuria [6]. Urinary parameters were not checked in Oxford
or RUNMC. Incidental increases particularly in alanine amino-
transferase and aspartate aminotransferase were reported in both
RUNMC and USMMVP. Severe increases (.2.5x ULN) were
found in five cases, three from USMMVP (twice at day 10, once at
day 14–16) and two from RUNMC II (day 16 and 17). All tests
normalized at the end of the trial.
Parasitemia by microscopy
Prepatent period between the four cohorts was significantly
different (Kruskall-Wallis p,0.001, Table 1), being longest in
Oxford and shortest in RUNMC I (Figure 1). When defining
prepatent period as time to one microscopically identified parasite,
with adjustment for microscopic threshold of detection, the
difference between prepatent period in RUNMC I and II was
no longer significant (Mann-Whitney p=0.28).
Parasitemia by Q-PCR
Data on parasite kinetics by Q-PCR were available for all
volunteers at all timepoints in RUNMC (both cohorts) and Oxford
and always preceeded parasitemia by microscopy.
Group mean parasite kinetics in RUNMC and Oxford display
highly synchronized, cyclical parasite growth (Figure 2). Peak
parasitemia was comparable between the cohorts despite different
microscopic detection threshold (p=0.06, Figure 3A), although
there seemed to be a trend towards higher parasitemia at
RUNMC after the threshold for microscopic parasite detection
changed. The first blood stage parasite growth cycle was
significantly lower in Oxford as compared to RUNMC
(p,0.001, Table 1 and Figure 3B), whereas the blood stage
multiplication rate was strikingly similar (geometric mean multi-
plication factor of 11.4 and 11.6 respectively, p=0.67). This
difference could not be explained by a methodological difference
in Q-PCR technique, as confirmed by an exchange of samples
between both institutions (data not shown). The length of the
prepatent period correlated with the first blood stage growth cycle
(Figure 4B) and showed a weak positive correlation with peak
parasitemia (Figure 4A).
Discussion
A comparison of clinical and parasitological data from more
than ten years’ experience with CHMI in RUNMC and Oxford
[6], reveals significant differences in time to microscopically
detected parasitemia whereas clinical symptoms are broadly
similar. Although there are several methodological differences
between the CHMI protocols that limit direct comparability, this
difference in prepatency likely results from variation in the mean
parasite burden in the first blood stage, possibly as a result of
different inoculum size, whilst blood stage multiplication factors
are equal.
The analysis of adverse events from 175 non-immune partic-
ipants of sporozoite challenge trials shows that serious adverse
events (grade 4) are rare. One serious cardiac adverse event was
reported; the true nature and patho-physiological explanation of
that event remains unclear [21]. Severe adverse events (grade 3)
related to clinical malaria occur in up to half of the volunteers and
persist for several days. We conclude that CHMI are generally
safe, but may lead to severe (grade 3) symptoms, though not
serious adverse events, in a significant proportion of subjects.
Several precautions are taken in both institutions to ensure safety
of volunteers, such as 24-hour phone access, medic-alert cards and
emergency contact procedures. Nevertheless, the exposure of
volunteers to the likelihood of some severe adverse events should
be carefully weighed against the benefits of the information to be
gained [22].
We find significant differences in frequencies of fever, fatigue,
arthralgia and chills between institutions. Cohorts with a longer
prepatent period or a higher peak parasitemia do not consistently
show a higher frequency of adverse events. These data, combined
with methodological differences in the recording of adverse events
(e.g. home-monitoring of oral temperature in RUNMC), lead us to
conclude that biologically relevant variation in patho-physiology
between institutions seems unlikely. Nevertheless, standardized
assessment of adverse events and harmonization of solicited events
would advance the interpretability and comparability of CHMI in
different settings worldwide.
Laboratory safety parameters show a severe decrease in platelet
count (,100610
9/l) in at least 7.5% of volunteers, as has been
studied by de Mast et al. [23,24]. Not all centers routinely perform
daily follow-up of platelets, so the actual occurrence of severe
thrombocytopenia may be higher. Platelet count decreases could
be predicted by baseline thrombocyte counts and the duration of
blood stage parasitemia, corroborating field data where parasite
Figure 1. Time to microscopically detected parasitemia by
cohort. Survival curve for four cohorts: RUNMC I (orange), RUNMC II
(blue), USMMVP (interrupted grey line) and Oxford (green).
doi:10.1371/journal.pone.0038434.g001
Figure 2. Geometric mean parasite density by Q-PCR per
cohort. Three cohorts are depicted RUNMC I (orange), RUNMC II (blue)
and Oxford (green).
doi:10.1371/journal.pone.0038434.g002
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bleeding or thrombogenic complications are not reported, in trials
where longer parasitemia is expected, platelet count monitoring
should be considered.
An increase in threshold for microscopic detection of parasites
leads to a prolonged prepatent period but not an increase in the
number of adverse events, as illustrated by comparing the
RUNMC I and II cohorts. Standardized reading of blood smears
is thus essential to harmonize trial endpoints worldwide; recent
efforts by the WHO have resulted in a proposed harmonization
document (Laurens MB, Roestenberg M, and Moorthy VS manuscript in
preparation). Variability in prepatent period among institutions,
however, cannot be explained solely by microscopy methodology.
A detailed analysis of parasitemia by Q-PCR revealed a ,10 fold
difference in the parasite burden during the first blood stage
growth cycle. Taking into account a replication factor of
approximately 10 every 48 hours, this difference accounts for a
48 hour shorter prepatent period at RUNMC. The variation in
parasite load may reflect variation in liver stage development of
the parasites or, alternatively, the number of inoculated parasites.
The number of inoculated parasites is estimated to vary widely
(ranging from 5–10 [26] to 100–300 sporozoites per bite [27,28]).
Whether the intensity of mosquito infection (e.g. sporozoite
salivary gland load) or exposure time influences the number of
sporozoites inoculated is controversial [29,30]. However, also a
formal relation between the number of parasites inoculated and
prepatent period has never been established [31,7,32,30,28,33].
Similarly, the role of mosquito infectivity (i.e. number of
sporozoites per mosquito), parasite strain (3D7 vs NF54), exposure
time (5 vs 10 minutes) or viability of inoculated sporozoites in
determining the inoculated dose is unclear [31,30]. Efforts to
standardize the sporozoite dose should ideally be tested for their
impact on comparability and reproducibility of CHMI. Standard-
ization may be achieved by harmonization of mosquito breeding
Figure 3. Statistics of Q-PCR parasitemia per cohort. Peak
parasitemia (A, one-way ANOVA p=0.13), geometric mean parasitemia
during the first blood stage parasite multiplication cycle, day 6.5 to 8.5
(B, one-way ANOVA p,0.001) and blood stage multiplication factor (C,
one-way ANOVA p=0.97) per cohort. Individual data is plotted, lines
represent geometric means. The threshold of detection of parasites by
Q-PCR was 20 parasites/ml blood. Any CT value .45 was assigned a
parasitemia of 10 parasites/ml.
doi:10.1371/journal.pone.0038434.g003
Figure 4. Correlation of Q-PCR parasitemia with prepatent
period. Correlation between peak parasitemia (A) or geometric mean
parasitemia during the first multiplication cycle from day 6.5 to day 8.5
(B) with prepatent period (R
2=0.27 and 20.73, p=0.006 and
p=,0.001, respectively). Prepatent period was defined as the time
between exposure to infectious mosquito bites until detection of blood
stage parasites by microscopy.
doi:10.1371/journal.pone.0038434.g004
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sporozoites. CHMI trials are underway to test the infectiousness of
cryopreserved sporozoites by needle injection (NCT01086917)
[34].
We show that blood stage parasite growth is cyclical and highly
synchronous within and between institutions. Importantly, the
duration of parasite liver stage development as well as the blood
stage multiplication rate are highly reproducible. Thus vaccine
efficacy can be robustly evaluated in any of the CHMI centers if a
non-protected, malaria-naı ¨ve control group is included.
CHMI trials do not fully mimic conditions in endemic regions
where pre-existing immunity may augment or impair vaccine
efficacy. A limited number of comparisons between Phase IIa
preliminary efficacy trials and Phase IIb field efficacy trials shows
that results are generally in line, but more comparisons are
required before definite conclusions can be drawn [2]. Another
potential difference is reflected by the almost instant delivery of
parasites by five infected mosquitoes, which has been considered
unnatural and a stringent test for vaccine-induced immune
responses [35]. However, although the frequency of infectious
mosquito bites is generally lower in malaria-endemic areas, intense
transmission can occur. A person may be subjected to 35–96
mosquito bites per night, and in certain areas approximately 10%
of mosquitoes are infected with Pf [36].
The present data show that CHMI can be safely conducted, but
will lead to grade 3 adverse events in a proportion of volunteers.
The primary parasitological outcome of such experiments is highly
reproducible within institutions but may vary between trial
centers. With an increasing number of CHMI centers being
installed, priority should be given to initiatives to standardize
challenge procedures [37]. The implementation of guidelines will
enhance the comparability of CHMI; a critical and indispensable
component of malaria vaccine development worldwide.
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